Thrombotic processes in multiple sclerosis as manifestation of innate immune activation

Frontiers in Neurology

Volumn 5 JUL, Issue , 2014, Pages

  Koudriavtseva, Tatiana ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Autoimmunity; Infection; Innate immunity; Multiple sclerosis; Thrombosis

Indexed keywords

DERMATAN SULFATE; DROTRECOGIN; HEPARIN; HIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; METHYLPREDNISOLONE;

ARTICLE; BLOOD CLOTTING; BRAIN PERFUSION; DISEASE ASSOCIATION; DRUG EFFECT; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; GENETIC ASSOCIATION; HUMAN; INFLAMMATION; INNATE IMMUNITY; LOW DRUG DOSE; LUMBAR PUNCTURE; MULTIPLE SCLEROSIS; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; RISK FACTOR; THROMBOSIS; VASCULAR DISEASE; VEIN BLOOD FLOW; VENOUS THROMBOEMBOLISM;

EID: 84904387219     PISSN: None     EISSN: 16642295     Source Type: Journal    
DOI: 10.3389/fneur.2014.00119     Document Type: Article

References (53)

1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple Sclerosis. N Engl J Med (2000) 343(13):938-52.
2. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol (2005) 23:683-747. doi: 10.1146/annurev.immunol.23.021704.115707
3. Disanto G, Morahan JM, Barnett MH, Giovannoni G, Ramagopalan SV. The evidence for a role of B cells in multiple sclerosis. Neurology (2012) 78(11):823-32. doi:10.1212/WNL.0b013e318249f6f0
4. Weiner HL. A shift from adaptive to innate immunity: a potential mechanism of disease progression in multiple sclerosis. J Neurol (2008) 255(Suppl 1):3-11. doi:10.1007/s00415-008-1002-8
5. Gandhi R, Laroni A, Weiner HL. Role of the innate immune system in the pathogenesis of multiple sclerosis. J Neuroimmunol (2010) 221(1-2):7-14. doi:10.1016/j.jneuroim.2009.10.015
6. Mayo L, Quintana FJ, Weiner HL. The innate immune system in demyelinating disease. Immunol Rev (2012) 248(1):170-87. doi:10.1111/j.1600-065X.2012.01135.x
7. Esmon CT. Interactions between the innate immune and blood coagulation systems. Trends Immunol (2004) 25(10):536-42. doi:10.1016/j.it.2004.08.003
8. Esmon CT, Xu J, Lupu F. Innate immunity and coagulation. J Thromb Haemost (2011) 9(Suppl 1):182-8. doi:10.1111/j.1538-7836.2011.04323.x
9. Esmon CT. Protein C anticoagulant system - anti-inflammatory effects. Semin Immunopathol (2012) 34(1):127-32. doi:10.1007/s00281-011-0284-6
10. Danckwardt S, Hentze MW, Kulozik AE. Pathologies at the nexus of blood coagulation and inflammation: thrombin in hemostasis, cancer, and beyond. J Mol Med (Berl) (2013) 91(11):1257-71. doi:10.1007/s00109-013-1074-5
11. Christensen S, Farkas DK, Pedersen L, Miret M, Christiansen CF, Sørensen HT. Multiple sclerosis and risk of venous thromboembolism: a population-based cohort study. Neuroepidemiology (2012) 38(2):76-83. doi:10.1159/000335496
12. Christiansen CF. Risk of vascular disease in patients with multiple sclerosis: a review. Neurol Res (2012) 34(8):746-53. doi:10.1179/1743132812Y.0000000051
13. Ramagopalan SV, Wotton CJ, Handel AE, Yeates D, Goldacre MJ. Risk of venous thromboembolism in people admitted to hospital with selected immune-mediated diseases: record-linkage study. BMC Med (2011) 9:1. doi:10.1186/1741-7015-9-1
14. Zöller B, Li X, Sundquist J, Sundquist K. Autoimmune diseases and venous thromboembolism: a review of the literature. Am J Cardiovasc Dis (2012) 2(3):171-83.
15. Ocak G, Vossen CY, Verduijn M, Dekker FW, Rosendaal FR, Cannegieter SC, et al. Risk of venous thrombosis in patients with major illnesses: results from the MEGA study. J Thromb Haemost (2013) 11(1):116-23. doi:10.1111/jth.12043
16. Vandenberghe N, Debouverie M, Anxionnat R, Clavelou P, Bouly S, Weber M. Cerebral venous thrombosis in four patients with multiple sclerosis. Eur J Neurol (2003) 10(1):63-6. doi:10.1046/j.1468-1331.2003.00513.x
17. Maurelli M, Bergamaschi R, Candeloro E, Todeschini A, Micieli G. Cerebral venous thrombosis and demyelinating diseases: report of a case in a clinically isolated syndrome suggestive of multiple sclerosis onset and review of the literature. Mult Scler (2005) 11(2):242-4. doi:10.1191/1352458505ms1125cr
18. Kalanie H, Harandi AA, Alidaei S, Heidari D, Shahbeigi S, Ghorbani M. Venous thrombosis in multiple sclerosis patients after high-dose intravenous methylprednisolone: the preventive effect of enoxaparin. Thrombosis (2011) 2011:785459. doi:10.1155/2011/785459
19. Presicci A, Garofoli V, Simone M, Campa MG, Lamanna AL, Margari L. Cerebral venous thrombosis after lumbar puncture and intravenous high dose corticosteroids: a case report of a childhood multiple sclerosis. Brain Dev (2013) 35(6):602-5. doi:10.1016/j.braindev.2012.09.001
20. International Multiple Sclerosis Genetics Consortium, Wellcome Trust Case Control Consortium, Sawcer S, Hellenthal G, Pirinen M, Spencer CC, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature (2011) 476(7359):214-9. doi:10.1038/nature10251
21. Kaplanski G, Marin V, Fabrigoule M, Boulay V, Benoliel AM, Bongrand P, et al. Thrombin-activated human endothelial cells support monocyte adhesion in vitro following expression of intercellular adhesion molecule-1 (ICAM-1; CD54) and vascular cell adhesion molecule-1 (VCAM-1; CD106). Blood (1998) 92(4):1259-67.
22. Horstman LL, Jy W, Ahn YS, Zivadinov R, Maghzi AH, Etemadifar M, et al. Role of platelets in neuroinflammation: a wide-angle perspective. J Neuroinflammation (2010) 7:10. doi:10.1186/1742-2094-7-10
23. Nurden AT. Platelets, inflammation and tissue regeneration. Thromb Haemost (2011) 105(Suppl 1):S13-33. doi:10.1160/THS10-11-0720
24. Behari M, Shrivastava M. Role of platelets in neurodegenerative diseases: a universal pathophysiology. Int J Neurosci (2013) 123(5):287-99. doi:10.3109/00207454.2012.751534
25. Horstman LL, Jy W, Ahn YS, Maghzi AH, Etemadifar M, Alexander JS, et al. Complement in neurobiology. Front Biosci (2011) 16:2921-60. doi:10.2741/3890
26. Veerhuis R, Nielsen HM, Tenner AJ. Complement in the brain. Mol Immunol (2011) 48(14):1592-603. doi:10.1016/j.molimm.2011.04.003
27. Ingram G, Hakobyan S, Hirst CL, Harris CL, Loveless S, Mitchell JP, et al. Systemic complement profiling in multiple sclerosis as a biomarker of disease state. Mult Scler (2012) 18(10):1401-11. doi:10.1177/1352458512438238
28. D'Haeseleer M, Cambron M, Vanopdenbosch L, De Keyser J. Vascular aspects of multiple sclerosis. Lancet Neurol (2011) 10:657-66. doi:10.1016/S1474-4422(11)70105-3
29. Fog T. The topography of plaques in multiple sclerosis with special reference to cerebral plaques. Acta Neurol Scand Suppl (1965) 1965(15):1-161.
30. Zamboni P, Galeotti R, Menegatti E, Malagoni AM, Tacconi G, Dall'Ara S, et al. Chronic cerebrospinal venous insufficiency in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry (2009) 80(4):392-9. doi:10.1136/jnnp.2008.157164
31. Comi G, Battaglia MA, Bertolotto A, Del Sette M, Ghezzi A, Malferrari G, et al. Observational case-control study of the prevalence of chronic cerebrospinal venous insufficiency in multiple sclerosis: results from the CoSMo study. Mult Scler (2013) 19(11):1508-17. doi:10.1177/1352458513501231
32. Traboulsee AL, Knox KB, Machan L, Zhao Y, Yee I, Rauscher A, et al. Prevalence of extracranial venous narrowing on catheter venography in people with multiple sclerosis, their siblings, and unrelated healthy controls: a blinded, case-control study. Lancet (2014) 383(9912):138-45. doi:10.1016/S0140-6736(13)61747-X
33. Salvi F, Bartolomei I, Buccellato E, Galeotti R, Zamboni P. Venous angioplasty in multiple sclerosis: neurological outcome at two years in a cohort of relapsing-remitting patients. Funct Neurol (2012) 27(1):55-9.
34. Courville CB. The effects of heparin in acute exacerbations of multiple sclerosis. Observations and deductions. Bull Los Angel Neuro Soc (1959) 24:187-96.
35. Maschmeyer J, Shearer R, Lonser E, Spindle DK. Heparin potassium in the treatment of chronic multiple sclerosis. Bull Los Angel Neuro Soc (1961) 26:165-71.
36. Zivadinov R. Is there a link between the extracranial venous system and central nervous system pathology? BMC Med (2013) 11:259. doi:10.1186/1741-7015-11-259
37. Zivadinov R, Poloni GU, Marr K, Schirda CV, Magnano CR, Carl E, et al. Decreased brain venous vasculature visibility on susceptibility-weighted imaging venography in patients with multiple sclerosis is related to chronic cerebrospinal venous insufficiency. BMC Neurol (2011) 11:128. doi:10.1186/1471-2377-11-128
38. Kirk J, Plumb J, Mirakhur M, McQuaid S. Tight junctional abnormality in multiple sclerosis white matter affects all calibres of vessel and is associated with blood-brain barrier leakage and active demyelination. J Pathol (2003) 201(2):319-27. doi:10.1002/path.1434
39. Putnam TJ. Studies in multiple sclerosis: encephalitis and sclerotic plaques produced by venular obstruction. Arch Neurol Psychiatry (1935) 33:929-40. doi:10.1001/archneurpsyc.1935.02250170015002
40. Wakefield AJ, More LJ, Difford J, McLaughlin JE. Immunohistochemical study of vascular injury in acute multiple sclerosis. J Clin Pathol (1994) 47:129-33. doi:10.1136/jcp.47.2.129
41. Han MH, Hwang SI, Roy DB, Lundgren DH, Price JV, Ousman SS, et al. Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature (2008) 451(7182):1076-81. doi:10.1038/nature06559
42. Chapman J. Thrombin in inflammatory brain diseases. Autoimmun Rev (2006) 5(8):528-31. doi:10.1016/j.autrev.2006.02.011
43. Chapman J. Coagulation in inflammatory diseases of the central nervous system. Semin Thromb Hemost (2013) 39(8):876-80. doi:10.1055/s-0033-1357482
44. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature (2000) 407:258-64. doi:10.1038/35025229
45. Beilin O, Karussis DM, Korczyn AD, Gurwitz D, Aronovich R, Hantai D, et al. Increased thrombin inhibition in experimental autoimmune encephalomyelitis. J Neurosci Res (2005) 79(3):351-9. doi:10.1002/jnr.20270
46. Inaba Y, Ichikawa M, Inoue A, Itoh M, Kyogashima M, Sekiguchi Y, et al. Plasma thrombin-antithrombin III complex is associated with the severity of experimental autoimmune encephalomyelitis. J Neurol Sci (2001) 185:89-93. doi:10.1016/S0022-510X(01)00468-3
47. Marik C, Felts PA, Bauer J, Lassmann H, Smith KJ. Lesion genesis in a subset of patients with multiple sclerosis: a role for innate immunity? Brain (2007) 130(Pt 11):2800-15. doi:10.1093/brain/awm236
48. Akassoglou K, Adams RA, Bauer J, Mercado P, Tseveleki V, Lassmann H, et al. Fibrin depletion decreases inflammation and delays the onset of demyelination in a tumor necrosis factor transgenic mouse model for multiple sclerosis. Proc Natl Acad Sci USA (2004) 101:6698-703. doi:10.1073/pnas.0303859101
49. Inaba Y, Ichikawa M, Koh CS, Inoue A, Itoh M, Kyogashima M, et al. Suppression of experimental autoimmune encephalomyelitis by dermatan sulfate. Cell Immunol (1999) 198:96-102. doi:10.1006/cimm.1999.1588
50. Lider O, Baharav E, Mekori YA, Miller T, Naparstek Y, Vlodavsky I, et al. Suppression of experimental autoimmune diseases and prolongation of allograft survival by treatment of animals with low doses of heparins. J Clin Invest (1989) 83(3):752-6. doi:10.1172/JCI113953
51. Owens GP, Gilden D, Burgoon MP, Yu X, Bennett JL. Viruses and multiple sclerosis. Neuroscientist (2011) 17(6):659-76. doi:10.1177/1073858411386615
52. Sibley WA, Bamford CR, Clark K. Clinical viral infections and multiple sclerosis. Lancet (1985) 1(8441):1313-5. doi:10.1016/S0140-6736(85)92801-6
53. Mechelli R, Umeton R, Policano C, Annibali V, Coarelli G, Ricigliano VA, et al. A "candidate-interactome" aggregate analysis of genome-wide association data in multiple sclerosis. PLoS One (2013) 8(5):e63300. doi:10.1371/journal.pone.0063300